Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 May;59(5):667–673. doi: 10.1038/bjc.1989.138

Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice.

M I Walton 1, N M Bleehen 1, P Workman 1
PMCID: PMC2247237  PMID: 2736198

Abstract

We have investigated the effects of localised tumour hyperthermia (LTH; 43.5 degrees C x 30 min) on the acute toxicity and pharmacokinetics of the hypoxic cell sensitizer pimonidazole (Ro 03-8799) in mice. There were three treatment groups: unrestrained controls, sham-treated and LTH treated mice. LTH had minimal effects on the acute toxicity (LD50/7d) of pimonidazole with no significant difference between the three treatment groups. Pharmacokinetic studies were carried out at the maximum tolerated dose (MTD; approximately 60% LD50) of 437 micrograms g-1 i.v. in plasma, brain and tumour. Sham tumour treatment consistently increased plasma drug concentrations compared to unrestrained controls but had minimal effects on the elimination t1/2. The AUC0-infinitive was increased by 35% and the plasma clearance decreased by 26%. By contrast, LTH had minimal effects on these parameters compared to sham treatment. Brain pimonidazole concentrations were increased in restrained mice (sham and LTH treatments) compared to unrestrained controls, but average brain/plasma ratios were similar in all three groups at between 400 and 500%. Sham tumour treatment markedly reduced peak tumour pimonidazole concentrations compared to unrestrained controls giving a 29% lower AUC0-180min. Average tumour/plasma ratios were reduced from 236 to 129%. The most important finding was that LTH further reduced pimonidazole tumour concentrations, giving a 31% lower AUC0-180 min compared to sham treated tumours. Tumour/plasma ratios for pimonidazole were reduced by 41%. Plasma exposure to the pimonidazole N-oxide metabolite, Ro 31-0313, was unaltered by LTH. The markedly reduced drug concentrations in heated tumours may be a result of hyperthermia-stimulated bioreductive drug activation.

Full text

PDF
667

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J. G., Dische S., Lenox-Smith I., Malcolm S. L., Saunders M. I. The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans. Eur J Clin Pharmacol. 1984;27(4):483–489. doi: 10.1007/BF00549599. [DOI] [PubMed] [Google Scholar]
  2. Arcangeli G., Overgaard J., Gonzalez Gonzalez D., Shrivastava P. N. International Clinical Trials in Radiation Oncology. Hyperthermia trials. Int J Radiat Oncol Biol Phys. 1988;14 (Suppl 1):S93–109. [PubMed] [Google Scholar]
  3. Bartelink H., Bleehen N. M., Phillips T. L. International Clinical Trials in Radiation Oncology. Chemical modifiers. Int J Radiat Oncol Biol Phys. 1988;14 (Suppl 1):S39–S49. [PubMed] [Google Scholar]
  4. Bicher H. I., Hetzel F. W., Sandhu T. S., Frinak S., Vaupel P., O'Hara M. D., O'Brien T. Effects of hyperthermia on normal and tumor microenvironment. Radiology. 1980 Nov;137(2):523–530. doi: 10.1148/radiology.137.2.7433686. [DOI] [PubMed] [Google Scholar]
  5. Bleehen N. M., Walton M. I., Workman P. Interactions of hyperthermia with hypoxic cell sensitisers. Recent Results Cancer Res. 1988;109:136–148. doi: 10.1007/978-3-642-83263-5_16. [DOI] [PubMed] [Google Scholar]
  6. Dennis M. F., Stratford M. R., Wardman P., Watts M. E. Cellular uptake of misonidazole and analogues with acidic or basic functions. Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Jun;47(6):629–643. doi: 10.1080/09553008514550871. [DOI] [PubMed] [Google Scholar]
  7. Dische S., Saunders M. I., Anderson P., Stratford M. R., Minchinton A. Clinical experience with nitroimidazoles as radiosensitizers. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):335–338. doi: 10.1016/0360-3016(82)90634-4. [DOI] [PubMed] [Google Scholar]
  8. Dodion P., Riggs C. E., Jr, Akman S. R., Bachur N. R. Effect of hyperthermia on the in vitro metabolism of doxorubicin. Cancer Treat Rep. 1986 May;70(5):625–629. [PubMed] [Google Scholar]
  9. Dudar T. E., Jain R. K. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res. 1984 Feb;44(2):605–612. [PubMed] [Google Scholar]
  10. Dvorchik B. H., Vessell E. S. Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clin Pharmacol Ther. 1978 Jun;23(6):617–623. doi: 10.1002/cpt1978236617. [DOI] [PubMed] [Google Scholar]
  11. Evanochko W. T., Ng T. C., Lilly M. B., Lawson A. J., Corbett T. H., Durant J. R., Glickson J. D. In vivo 31P NMR study of the metabolism of murine mammary 16/C adenocarcinoma and its response to chemotherapy, x-radiation, and hyperthermia. Proc Natl Acad Sci U S A. 1983 Jan;80(2):334–338. doi: 10.1073/pnas.80.2.334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gomer C. J., Johnson R. J. Relationship between misonidazole toxicity and core temperature in C3H mice. Radiat Res. 1979 May;78(2):329–333. [PubMed] [Google Scholar]
  13. Herman T. S., Teicher B. A., Jochelson M., Clark J., Svensson G., Coleman C. N. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hyperthermia. 1988 Mar-Apr;4(2):143–158. doi: 10.3109/02656738809029305. [DOI] [PubMed] [Google Scholar]
  14. Honess D. J., Workman P., Morgan J. E., Bleehen N. M. Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse. Br J Cancer. 1980 Apr;41(4):529–540. doi: 10.1038/bjc.1980.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Magin R. L., Cysyk R. L., Litterst C. L. Distribution of adriamycin in mice under conditions of local hyperthermia which improve systemic drug therapy. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):203–210. [PubMed] [Google Scholar]
  16. Malcolm S. L., Lee A., Groves J. K. High-performance liquid chromatographic analysis of the new hypoxic cell radiosensitiser, Ro 03-8799, in biological samples. J Chromatogr. 1983 Apr 8;273(2):327–333. doi: 10.1016/s0378-4347(00)80953-6. [DOI] [PubMed] [Google Scholar]
  17. Mella O. Combined hyperthermia and cis-diamminedichloroplatinum in BD IX rats with transplanted BT4A tumours. Int J Hyperthermia. 1985 Apr-Jun;1(2):171–183. doi: 10.3109/02656738509029283. [DOI] [PubMed] [Google Scholar]
  18. Mittal B., Emami B., Sapareto S. A., Taylor F. H., Abrath F. G. Effects of sequencing of the total course of combined hyperthermia and radiation on the RIF-1 murine tumor. Cancer. 1984 Dec 15;54(12):2889–2897. doi: 10.1002/1097-0142(19841215)54:12<2889::aid-cncr2820541213>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  19. Overgaard J. Effect of local hyperthermia on the acute toxicity of misonidazole in mice. Br J Cancer. 1979 Jan;39(1):96–98. doi: 10.1038/bjc.1979.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Overgaard J. Effect of misonidazole and hyperthermia on the radiosensitivity of a C3H mouse mammary carcinoma and its surrounding normal tissue. Br J Cancer. 1980 Jan;41(1):10–21. doi: 10.1038/bjc.1980.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Proceedings of the American Society for Therapeutic Radiology and Oncology. 28th annual meeting. November 2-7, 1986, Los Angeles, California. Abstracts. Int J Radiat Oncol Biol Phys. 1986 Nov;12 (Suppl 1):1–195. [PubMed] [Google Scholar]
  22. Rauth A. M. Pharmacology and toxicology of sensitizers: mechanism studies. Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1293–1300. doi: 10.1016/0360-3016(84)90335-3. [DOI] [PubMed] [Google Scholar]
  23. Roberts J. T., Bleehen N. M., Walton M. I., Workman P. A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics. Br J Radiol. 1986 Feb;59(698):107–116. doi: 10.1259/0007-1285-59-698-107. [DOI] [PubMed] [Google Scholar]
  24. Sapareto S. A., Hopwood L. E., Dewey W. C. Combined effects of X irradiation and hyperthermia on CHO cells for various temperatures and orders of application. Radiat Res. 1978 Feb;73(2):221–233. [PubMed] [Google Scholar]
  25. Stratford M. R., Dennis M. F., Watts M. E., Watfa R. R. Radiosensitizer-DNA interactions. Br J Radiol. 1988 Sep;61(729):860–861. doi: 10.1259/0007-1285-61-729-860-b. [DOI] [PubMed] [Google Scholar]
  26. Taylor Y. C., Rauth A. M. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res. 1978 Sep;38(9):2745–2752. [PubMed] [Google Scholar]
  27. Twentyman P. R., Kallman R. F., Brown J. M. The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1255–1260. doi: 10.1016/0360-3016(79)90649-7. [DOI] [PubMed] [Google Scholar]
  28. Walton M. I., Bleehen N. M., Workman P. Heat-stimulated nitroreductive bioactivation of the 2-nitroimidazole benznidazole in vitro. Biochem Pharmacol. 1987 Aug 15;36(16):2627–2632. doi: 10.1016/0006-2952(87)90542-9. [DOI] [PubMed] [Google Scholar]
  29. Walton M. I., Bleehen N. M., Workman P. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice. Br J Cancer. 1987 May;55(5):469–476. doi: 10.1038/bjc.1987.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wasserman T. H., Phillips T. L., Johnson R. J., Gomer C. J., Lawrence G. A., Sadee W., Marques R. A., Levin V. A., VanRaalte G. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys. 1979 Jun;5(6):775–786. doi: 10.1016/0360-3016(79)90061-0. [DOI] [PubMed] [Google Scholar]
  31. White R. A., Workman P. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs. Br J Cancer. 1980 Feb;41(2):268–276. doi: 10.1038/bjc.1980.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wike-Hooley J. L., Haveman J., Reinhold H. S. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol. 1984 Dec;2(4):343–366. doi: 10.1016/s0167-8140(84)80077-8. [DOI] [PubMed] [Google Scholar]
  33. Williams M. V., Denekamp J., Minchinton A. I., Stratford M. R. In vivo assessment of basic 2-nitroimidazole radiosensitizers. Br J Cancer. 1982 Jul;46(1):127–137. doi: 10.1038/bjc.1982.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wondergem J., Haveman J., van der Schueren E., van den Hoeven H., Breur K. Effect of hyperthermia and misonidazole on the radiosensitivity of a transplantable murine tumor: influence of factors modifying the fraction of hypoxic cells. Int J Radiat Oncol Biol Phys. 1982 Aug;8(8):1323–1331. doi: 10.1016/0360-3016(82)90582-x. [DOI] [PubMed] [Google Scholar]
  35. Workman P., Brown J. M. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol. 1981;6(1):39–49. doi: 10.1007/BF00253009. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES